A large observational study suggests eating a plant-rich diet could reduce the risk of developing severe COVID-19.
Eating a plant rich diet reduces risk of developing COVID-19 – King’s College London Original study: Diet quality and risk and severity of COVID-19: a prospective cohort study – Gut
The post A large observational study suggests eating a plant-rich diet could reduce the risk of developing severe COVID-19. appeared first on Links Medicus.
Perspective | The plan to stop every respiratory virus at once – “The benefits of ventilation reach far beyond the coronavirus. What if we stop taking colds and flus for granted, too?”
The Plan to Stop Every Respiratory Virus at Once – The Atlantic Related: Recommendations for ventilation of indoor spaces to reduce COVID-19 transmission. We studied how to reduce airborne COVID spread in hospitals. Here’s what we learnt. Report: Improved ventilation essential to safe use of buildings and public spaces, say leading engineers. WHO: Roadmap to […]
The post Perspective | The plan to stop every respiratory virus at once – “The benefits of ventilation reach far beyond the coronavirus. What if we stop taking colds and flus for granted, too?” appeared first on Links Medicus.
[Preprint] RCT: Additional heterologous vs. homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination.
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial – medRxiv Commentary on Twitter (thread – click for more) Results of 60-person randomized trial of 3rd shot of mRNA or AZ vax in people on rituximab who didn't seroconvert after BNT-Pfizer (most) […]
The post [Preprint] RCT: Additional heterologous vs. homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination. appeared first on Links Medicus.
AstraZeneca bosses warn against rush for boosters – “giving the most vulnerable, who may not have built up a full immune response from the first two, a third, top-up dose is “sensible”. But any decision to give a third, booster jab “to large swathes of th
AstraZeneca bosses warn against rush for boosters – BBC Commentary on Twitter (thread – click for more) "Moving too quickly to boost across the entire adult population will deprive us of these insights, leaving this important decision to rest on limited data," Mr Soriot and Sir Mene write.https://t.co/xTAk7yyu5G — The Sharing Scientist (@ScienceShared) September […]
The post AstraZeneca bosses warn against rush for boosters – “giving the most vulnerable, who may not have built up a full immune response from the first two, a third, top-up dose is “sensible”. But any decision to give a third, booster jab “to large swathes of the population”, to extend their protection from the first two, must be based on clinical data”. appeared first on Links Medicus.
[Preprint] Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera.
Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera – bioRxiv Related: United States boosts tracking of coronavirus strains as Mu variant draws scrutiny – Science Commentary on Twitter (thread – click for more) ?Bad news on #MuVariant—Japanese scientists: "Mu variant is highly resistant to sera from convalescent & [Pfizer]-vaccinated people. […]
The post [Preprint] Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera. appeared first on Links Medicus.
Spread of Delta SARS-CoV-2 variant driven by a combination of immune escape and increased infectivity.
News release: Spread of Delta SARS-CoV-2 variant driven by combination of immune escape and increased infectivity – University of Cambridge Original article: SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion – Nature
The post Spread of Delta SARS-CoV-2 variant driven by a combination of immune escape and increased infectivity. appeared first on Links Medicus.
Cochrane review: evidence is insufficient to draw meaningful conclusions if SARS‐CoV‐2-specific monoclonal antibodies are effective in the treatment of COVID-19.
Summary: Are laboratory-made, COVID-19-specific monoclonal antibodies an effective treatment for COVID-19? – Cochrane Library Original review: SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 – Cochrane Library
The post Cochrane review: evidence is insufficient to draw meaningful conclusions if SARS‐CoV‐2-specific monoclonal antibodies are effective in the treatment of COVID-19. appeared first on Links Medicus.
Isn’t it time to abandon ARDS? The COVID-19 lesson.
Isn’t it time to abandon ARDS? The COVID-19 lesson – Critical Care Commentary on Twitter #CritCare #OA #Gattinoni & #Marini: Keeping or abandoning #ARDS? ▶️ pros ▶️ conshttps://t.co/tIhusXT2S7#FOAMed #FOAMcc #BMC #COVID19 #Rx #RCT #PEEP #respiratory_failure #Personalized pic.twitter.com/M6aoiSAn3m — Critical Care (@Crit_Care) September 7, 2021
The post Isn’t it time to abandon ARDS? The COVID-19 lesson. appeared first on Links Medicus.
Supplement: Current Issues in Venous Thromboembolism.
Homepage: Current Issues in Venous Thromboembolism – Postgraduate Medicine Editorial: Current issues in venous thromboembolism A review of upper extremity deep vein thrombosis Outpatient treatment of emergency department patients diagnosed with venous thromboembolism Venous thromboembolism prophylaxis in high-risk orthopedic and cancer surgery Prophylaxis and treatment of COVID-19 related venous thromboembolism Challenges in the diagnostic approach […]
The post Supplement: Current Issues in Venous Thromboembolism. appeared first on Links Medicus.
The Lancet Series: Interstitial Lung Disease 2021.
Homepage: Interstitial Lung Disease 2021 (free registration required for all articles) Disease pathology in fibrotic interstitial lung disease: is it all about usual interstitial pneumonia? Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities Treatment of fibrotic interstitial lung disease: current approaches and future directions Interstitial lung diseases: quo vadis? Moving beyond usual interstitial […]
The post The Lancet Series: Interstitial Lung Disease 2021. appeared first on Links Medicus.